Trial Profile
Phase III: UbLiTuximab In Multiple Sclerosis Treatment Effects (ULTIMATE I STUDY)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Apr 2024
Price :
$35
*
At a glance
- Drugs Ublituximab (Primary) ; Teriflunomide
- Indications Multiple sclerosis
- Focus Registrational; Therapeutic Use
- Acronyms ULTIMATE I
- Sponsors TG Therapeutics Inc
- 15 Apr 2024 According to TG Therapeutics, Inc media release, company announced presentation of data from ULTIMATE I & II Phase 3 trials evaluating BRIUMVI (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2024 American Academy of Neurology (AAN) annual meeting, being held in Denver, Colorado, on Wed, Apr 17, from 8:00 AM - 9:00 AM MST.
- 08 Mar 2024 According to TG Therapeutics, Inc media release, data from this study will be presented at the upcoming American Academy of Neurology 2024 annual meeting, being held April 13 - 18, 2024, in Dever, Colorado.
- 20 Feb 2024 According to TG Therapeutics, Inc media release, the schedule of data presentations highlighting data from the ULTIMATE I and II Phase 3 trials and the ENHANCE Phase 3b trial evaluating BRIUMVI(ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the upcoming Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual forum, being held February 29-March 2, 2024, in West Palm Beach, Florida.